For example, protein aggregation inhibitors have been widely investigated in academia for their potential to prevent the accumulation of proteins that occurs in many neurodegenerative disorders, including Batten disease.
Obstacles relate to functional differences between academia, where discovery occurs, and applied science, which lies mostly in the realm of the commercial sector.